Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Blood

• Publication date

  2002-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V100.1.194PMID 12070027
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bcl-2 antisense therapy in multiple myeloma.

  2004cited by this paper
• A Constitutive Cytoprotective Pathway Protects Endothelial Cells from Lipopolysaccharide-induced Apoptosis*

  2001cited by this paper
• The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6

  2001cited by this paper
• Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.

  2000cited by this paper
• Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells.

  2000cited by this paper
• Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.

  2000cited by this paper
• G(1) phase-dependent expression of bcl-2 mRNA and protein correlates with chemoresistance of human cancer cells.

  2000cited by this paper
• Phase-Dependent Expression of Bcl-2 mRNA and Protein Correlates with Chemoresistance of Human Cancer Cells

  2000cited by this paper
• IL‐6 up‐regulates Mcl‐1 in human myeloma cells through JAK / STAT rather than Ras / MAP kinase pathway

  1999cited by this paper
• Inhibition of Bcl-xL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli

  1999cited by this paper
• Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy

  1999cited by this paper
• Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders

  1999cited by this paper
• Bcl-2 antisense therapy in multiple myeloma.

  1999cited by this paper
• Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.

  1999cited by this paper
• Mcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cells

  1999cited by this paper
• bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study.

  1998cited by this paper
• BCL-X expression in multiple myeloma: possible indicator of chemoresistance.

  1998cited by this paper
• The Bcl-2 protein family: arbiters of cell survival.

  1998cited by this paper
• First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies.

  1997cited by this paper
• Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation.

  1997cited by this paper
• BCL-2 antisense therapy in patients with non-Hodgkin lymphoma.

  1997cited by this paper
• First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies.

  1997cited by this paper
• The anti‐apoptosis function of Bcl‐2 can be genetically separated from its inhibitory effect on cell cycle entry

  1997cited by this paper
• Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival.

  1996cited by this paper
• Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide.

  1996cited by this paper
• Bcl-2 protein expression is not related to short survival in multiple myeloma.

  1995cited by this paper
• The gp 130 family cytokines IL‐6, LIF and OSM but not IL‐11 can reverse the anti‐proliferative effect of dexamethasone on human myeloma cells

  1995cited by this paper
• Interleukin-6 prevents dexamethasone-induced myeloma cell death.

  1994cited by this paper
• MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.

  1993cited by this paper
• Optimal detection of apoptosis by flow cytometry depends on cell morphology.

  1993cited by this paper
• A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1).

  1993cited by this paper

• Disruption of oncogenic MCL-1-BAX/BAK interaction using integrase inhibitors: insights from a molecular docking and dynamic exploration

  2025cites this paper
• CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy.

  2025cites this paper
• Discovery of Macrocyclic Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors that Demonstrate Potent Cellular Efficacy and In Vivo Activity in a Mouse Solid Tumor Xenograft Model

  2025cites this paper
• Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study.

  2025cites this paper
• BCL2 inhibition for multiple myeloma and AL amyloidosis

  2025cites this paper
• Advances in RNA therapeutics and its delivery strategies against Multiple Myeloma.

  2025cites this paper
• Developing antisense therapeutics for multiple myeloma

  2025cites this paper
• KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis

  2024cites this paper
• Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent In Vivo Activities in Mouse Models of Hematological and Solid Tumors

  2024cites this paper
• Antisense oligonucleotides-based approaches for the treatment of multiple myeloma.

  2024cites this paper
• BCL-2 inhibition in haematological malignancies: Clinical application and complications.

  2024cites this paper
• The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges.

  2024cites this paper
• AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma

  2023cites this paper
• MCL-1 Inhibitor S63845 Distinctively Affects Intramedullary and Extramedullary Hematopoiesis

  2023cites this paper
• Theoretical Study on the Binding Properties of Inhibitors to Myeloid Cell Leukemia 1

  2023cites this paper
• Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma

  2022cites this paper
• Highly expressed genes in multiple myeloma cells – what can they tell us about the disease?

  2022cites this paper
• Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma

  2022cites this paper
• Mutation in MCL1 predicted loop to helix structural transition stabilizes MCL1–Bax binding interaction favoring cancer cell survival

  2022cites this paper
• IONIZING RADIATION AND CYTOKINES: THE ROLE IN THE PATHOGENESIS OF PLASMA CELL MYELOMA (LITERATURE REVIEW).

  2022cites this paper
• Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics

  2022cites this paper
• Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges

  2022cites this paper
• Multiple myeloma with t(11;14): unique biology and evolving landscape.

  2022cites this paper
• Mechanisms of venetoclax resistance and solutions

  2022cites this paper
• Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression

  2022cites this paper
• Future Developments in the Treatment of AL Amyloidosis

  2022cites this paper
• Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma

  2022cites this paper
• Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors.

  2021cites this paper
• Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma

  2021cites this paper
• Elevated USP9X drives early-to-late-stage oral tumorigenesis via stabilisation of anti-apoptotic MCL-1 protein and impacts outcome in oral cancers

  2021cites this paper
• Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets

  2021cites this paper
• Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells

  2021cites this paper
• A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma.

  2021cites this paper
• Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma

  2021cites this paper
• MCL1 participates in leptin-promoted mitochondrial fusion and contributes to drug resistance in gallbladder cancer

  2021cites this paper
• Epidemiology, genetics and treatment of multiple myeloma and precursor diseases

  2021cites this paper
• Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma

  2021influential citation
• Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma

  2021cites this paper
• BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma

  2021cites this paper
• BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines.

  2020cites this paper
• Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma

  2020cites this paper
• Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma

  2020cites this paper
• Simultaneous Profiling of DNA Copy Number Variations and Transcriptional Programs in Single Cells using RNA-seq

  2020cites this paper
• Exploring indole derivatives as myeloid cell leukaemia-1 (Mcl-1) inhibitors with multi-QSAR approach: a novel hope in anti-cancer drug discovery

  2020cites this paper
• MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents

  2020cites this paper
• Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer

  2020cites this paper
• Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance.

  2020cites this paper
• Structure-based Drug Design Strategies in the Development of Small Molecule Inhibitors Targeting Bcl-2 Family Proteins

  2020cites this paper
• Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy

  2020cites this paper
• Targeting MCL-1 in hematologic malignancies: Rationale and progress.

  2020influential citation
• The BCL-2 family members NOXA and BIM mediate fluorizoline-induced apoptosis in multiple myeloma cells.

  2020cites this paper
• How Good is Jarzynski’s Equality for Computer-Aided Drug Design?

  2020cites this paper
• Hot-Spots of Mcl-1 Protein.

  2020cites this paper
• SUMOylation of MCL1 protein enhances its stability by regulating the ubiquitin-proteasome pathway.

  2020cites this paper
• AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia

  2020cites this paper
• Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies

  2019cites this paper
• Novel targets for the treatment of relapsing multiple myeloma

  2019cites this paper
• Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells

  2019cites this paper
• STAT3: A Promising Therapeutic Target in Multiple Myeloma

  2019cites this paper
• Survival of Long-Lived Plasma Cells (LLPC): Piecing Together the Puzzle

  2019cites this paper
• Cancer Metabolism and the Evasion of Apoptotic Cell Death

  2019cites this paper
• MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells

  2019cites this paper
• Anticancer effect of pan‐PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance

  2019cites this paper
• Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma

  2019cites this paper
• Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.

  2019cites this paper
• C-Myc inhibition sensitizes pre-B ALL cells to the anti-tumor effect of vincristine by altering apoptosis and autophagy: Proposing a probable mechanism of action for 10058-F4.

  2019cites this paper
• BCL2 blockade overcomes MCL1 resistance in multiple myeloma

  2019cites this paper
• CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity

  2019cites this paper
• RNF6 promotes myeloma cell proliferation and survival by inducing glucocorticoid receptor polyubiquitination

  2019cites this paper
• DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells

  2018cites this paper
• Designing selective small molecule inhibitor screening through BH3 profiling

  2018cites this paper
• Selective targeting of antiapoptotic BCL‐2 proteins in cancer

  2018cites this paper
• Etude de l'implication de mécanismes épigénétiques dans la physiopathologie du myélome multiple et dans la différenciation plasmocytaire normale

  2018cites this paper
• Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma

  2018cites this paper
• Mcl‐1 targeting could be an intriguing perspective to cure cancer

  2018cites this paper
• An investigation into the efficacy of SVC112, a translation elongation inhibitor, in colorectal carcinoma and acute myeloid leukemia

  2018cites this paper
• Pleural Macrophages can Promote or Inhibit Apoptosis of Malignant Cells via Humoral Mediators Depending on Intracellular Signaling Pathways

  2018cites this paper
• 5‐Azacytidine specifically inhibits the NIH‐3T3 PCD process induced by TNF‐alpha and cycloheximide via affecting BCL‐XL

  2018cites this paper
• Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.

  2018cites this paper
• Stimulatory Effect of Indolic Hormone on As2O3 Cytotoxicity in Breast Cancer Cells: NF-κB-dependent Mechanism of Action of Melatonin

  2018cites this paper
• Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design.

  2018cites this paper
• Targeting Bcl-2 for the treatment of multiple myeloma

  2018cites this paper
• Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer

  2017cites this paper
• Targeting human telomerase RNA component using antisense oligonucleotide induces rapid cell death and increases ATO‐induced apoptosis in APL cells

  2017cites this paper
• A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma

  2017cites this paper
• Physicochemical, Microbiological and Sensory Properties of Yoghurt Processed by Addition of Rice Flour

  2017cites this paper
• University of Groningen Clinical and biological aspects of Multiple Myeloma

  2017cites this paper
• Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib.

  2017cites this paper
• Development of Methods for the Discovery of Small Molecule Biological Probes

  2017cites this paper
• Developing novel agents targeting the NF-κB pathway for the treatment of multiple myeloma

  2017cites this paper
• Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma

  2017cites this paper
• Azacytidine specifically inhibits the NIH-3 T 3 PCD process induced by TNF-alpha and cycloheximide via affecting BCL-XL † Running title : 5-azacytidine inhibits NIH-3 T 3 PCD via affecting BCL-XL

  2017cites this paper
• From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

  2017cites this paper
• Virtual screening for potential inhibitors of Mcl-1 conformations sampled by normal modes, molecular dynamics, and nuclear magnetic resonance

  2017cites this paper
• Function of myeloid cell leukaemia-1 and its regulative relations with hepatocellular carcinoma

  2017cites this paper
• Discovery of a Turn-On Fluorescent Probe for Myeloid Cell Leukemia-1 Protein.

  2017cites this paper
• The novel compound STK 405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo

  2017cites this paper
• YM155 exerts potent cytotoxic activity against quiescent (G0/G1) multiple myeloma and bortezomib resistant cells via inhibition of survivin and Mcl-1

  2017cites this paper
• Identifying the Right Patient for Bcl2 Inhibition in Myeloma

  2017cites this paper
• Why do BCL-2 inhibitors work and where should we use them in the clinic?

  2017cites this paper